For US residents only.

How Treatment May Help

Sandostatin LAR Depot

When you get a diagnosis of severe diarrhea and flushing associated with carcinoid syndrome, your first thought may be, “What now?” There’s a treatment option like Sandostatin® LAR Depot (octreotide acetate for injectable suspension). Sandostatin® (octreotide acetate) Immediate-release Injection is a medicine approved to treat the severe diarrhea and flushing associated with carcinoid syndrome. It may help you control your symptoms and live in the moment.

Treating patients for 30 years*

*Includes Sandostatin® (octreotide acetate) Immediate-release Injection and Sandostatin® LAR Depot (octreotide acetate for injectable suspension) for all approved indications.

Symptom Control You Can Count On

Here are results from a clinical study of 93 patients with carcinoid syndrome who were treated with Sandostatin LAR Depot or Sandostatin Immediate-release Injection.

A 6-month clinical trial of malignant carcinoid syndrome was performed in patients who had previously been shown to be responsive to Sandostatin Immediate-release Injection. Patients received 10-mg, 20-mg, or 30-mg doses of Sandostatin LAR Depot every 28 days or continued their Sandostatin Immediate-release Injection regimen. Patients receiving Sandostatin LAR Depot who experienced symptom flare-ups were permitted to use supplemental Sandostatin Immediate-release Injection until symptoms were again controlled to screening frequency.